EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe
Provides Foundation For Uptake Ahead Of Upcoming EU Pharmaceutical Legislation Reform
The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.
